0000000000329331

AUTHOR

Protti A.

showing 2 related works from this author

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

2014

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours and had their vital signs monitored hourly. Extended on-site monitoring was provided when required. RESULTS: Of the 906 p…

OncologyMaleNeurologyfingolimod multiple sclerosis treatment first dose safetyadministration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic useImmunosuppressive AgentSphingosineMultiple SclerosiAtrioventricular Blockadministration /&/ dosage/adverse effects/therapeutic useGeneral MedicineMiddle AgedTolerabilityPropylene GlycolFingolimoddrug therapyTolerabilityAnesthesiaCohortAdolescent Adult Atrioventricular Block; chemically induced/epidemiology Drug Therapy; Combination Female Humans Immunosuppressive Agents; administration /&/ dosage/adverse effects/therapeutic use Male Middle Aged Multiple Sclerosis; drug therapy Propylene Glycols; administration /&/ dosage/adverse effects/therapeutic use Sphingosine; administration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic use Young AdultCombinationDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAtrioventricular block; Bradycardia; Fingolimod; Multiple sclerosis; Safety; Tolerability; Adolescent; Adult; Atrioventricular Block; Drug Therapy Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult; Neurology (clinical)SafetyAtrioventricular block Bradicardia Multiple sclerosis Fingolimod Safety TolerabilityImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentClinical NeurologyYoung AdultFingolimod HydrochlorideInternal medicineBradycardiamedicineHumansNeurochemistryFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseClinical trialPropylene GlycolsAtrioventricular block Bradycardia Multiple sclerosis Fingolimod Safety Tolerabilitychemically induced/epidemiologyNeurology (clinical)business
researchProduct

Death in hospital following ICU discharge: insights from the LUNG SAFE study

2021

Abstract Background To determine the frequency of, and factors associated with, death in hospital following ICU discharge to the ward. Methods The Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE study was an international, multicenter, prospective cohort study of patients with severe respiratory failure, conducted across 459 ICUs from 50 countries globally. This study aimed to understand the frequency and factors associated with death in hospital in patients who survived their ICU stay. We examined outcomes in the subpopulation discharged with no limitations of life sustaining treatments (‘treatment limitations’), and the subpopulations with tre…

MaleARDSLUNG SAFEhealth care facilities manpower and servicesAcute hypoxemic respiratory failure; Acute respiratory distress syndrome; Hospital survival; ICU discharge; LUNG SAFEKaplan-Meier EstimateCritical Care and Intensive Care MedicineAcute hypoxemic respiratory failure; Acute respiratory distress syndrome; Hospital survival; ICU discharge; LUNG SAFE;0302 clinical medicineRisk Factors030212 general & internal medicineProspective StudiesProspective cohort studyAcute hypoxemic respiratory failureCOPDAcute respiratory distress syndromeICU dischargeMedical emergencies. Critical care. Intensive care. First aidMiddle AgedPatient DischargeLUNG SAFE.Intensive Care Unitsmedicine.anatomical_structureLung safeSOFA scoreFemaleRespiratory InsufficiencyAdultmedicine.medical_specialtyNOHospital survival03 medical and health sciencesSettore MED/41 - ANESTESIOLOGIAmedicineHumansddc:610Risk factorMortalityAgedLungRC86-88.9business.industryResearch030208 emergency & critical care medicinemedicine.diseaseLogistic Modelslnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Respiratory failureEmergency medicineObservational studybusiness
researchProduct